SCHEMBL5137696

SCHEMBL5137696

CCCCn1c(CN(Cc2ccccc2)Cc2cccc(C)c2C)cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.41
HSD11B1 P28845 2/20 0.36
C5AR1 P21730 1/20 0.35
PDE4B Q07343 2/20 0.34
NR1H3 Q13133 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ADORA2B P29275 1/20 0.33
BRD4 O60885 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
KMT2A Q03164 1/20 0.31
MAOB P27338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136720 0.93 TSHR (0.44) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135727 0.91 TSHR (0.39) TSHRHSD11B1C5AR1PDE4B
SCHEMBL5135257 0.90 TSHR (0.40) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5072278 0.89 TSHR (0.51) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5137296 0.89 TSHR (0.42) TSHRHSD11B1ALDH1A1
SCHEMBL5072389 0.87 TSHR (0.41) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135972 0.87 C5AR1 (0.54) TSHRC5AR1HSD17B10ALDH1A1LMNA
SCHEMBL5074850 0.87 TSHR (0.42) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135136 0.86 TSHR (0.40) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135385 0.86 TSHR (0.40) TSHRHSD11B1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed